DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type 2 diabetes FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure when added to standard of care WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive results from the landmark Phase […]